Analysis
Three biotech financings landed inside a single week, all betting on AI to accelerate drug discovery and development:
- Pathos AI — $237M Series E at $3B valuation (led by Bristol Myers Squibb, Oct 23): pairs the capital with a five-year, $55M data-licensing deal with Tempus AI covering roughly 200 petabytes of oncology data. Pulse coverage
- Star Therapeutics — $200M private financing (co-led by OrbiMed and Janus Henderson, Oct 23): a fresh vehicle from the team that sold Vega Therapeutics to Incyte for up to $2B in July. Pulse coverage
- Zai Lab — $250M PIPE (priced at $22.04 per ADS, Oct 23): funds a DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan. Pulse coverage
Combined, that's $687 million across three rounds in roughly 24 hours.
“Pulse coverage Combined, that's $687 million across three rounds in roughly 24 hours.”
The OrbiMed/Janus Henderson pairing is the more interesting data point for anyone tracking repeat biotech teams. The same investor group previously sold Vega Therapeutics to Incyte for up to $2 billion in July, and a Vega spinout, Electra Therapeutics, listed on Nasdaq as ETRA in September. Star Therapeutics is effectively the next vehicle from that same playbook, raised within weeks of the prior one closing out.
What the headline misses: these are three different stages and structures — a Series E with a strategic pharma lead, a private financing round, and a public-company PIPE — not three comparable primary rounds. Zai Lab's $250 million is dilution into an already-public company trading on Nasdaq, which behaves differently than Pathos AI's private Series E markup to $3 billion. Lumping them into one week-over-week total is useful for spotting capital flow, not for comparing valuations.
It's also a narrow sample: three rounds in one week is not evidence of a sustained re-rating of AI-drug-discovery capital, just that late-October happened to cluster some large, already-in-motion deals. The real test is whether a comparable cluster shows up again in November, or whether this week was simply calendar noise from deals that had been negotiating for months.
Bristol Myers Squibb leading Pathos AI's round directly, rather than licensing the technology later, is the detail worth watching longer-term: pharma majors writing primary-round checks into AI drug-discovery startups is a different capital-allocation decision than licensing deals, and it changes who captures the upside if the platform works.